Nanobodies as antivirals against rabies in experimentally infected mice
Authors:
- Washington Carlos AgostinhoWAWashington Carlos Agostinho
- Viviana ParreñoVPViviana Parreño
- Celina Guadalupe VegaCVCelina Guadalupe Vega
- Matias AdurizMAMatias Aduriz
- Carolina Moura de OliveiraCOCarolina Moura de Oliveira
- Sheila Olivera de Sousa SilvaSSSheila Olivera de Sousa Silva
- Joana AguiarJAJoana Aguiar
- Sueli Akemi TaniwakiSTSueli Akemi Taniwaki
- Paulo Eduardo BrandãoPBPaulo Eduardo Brandão
Open Access
- 1 January 2025
- journal article
- Published by FapUNIFESP (SciELO) in Revista do Instituto de Medicina Tropical de São Paulo
- Vol. 67, e63
Abstract
Despite its 100% lethality and approximately 59,000 human deaths every year, rabies still lacks an effective treatment. Numerous trials have aimed to impair the life cycle of Lyssavirus rabies (RABV), the primary worldwide lyssavirus causing rabies, but with limited success. Treatments targeting host factors and attempting to mitigate the damage caused by RABV have also been unsatisfactory. This article describes the effects of intracerebral transfection of anti-RABV recombinant monoclonal nanobodies as antivirals against rabies in vivo, in a post-exposure protocol. Mice were intranasally inoculated with the RABV CVS strain and, 72 h later, were injected via the intracerebral route with two different anti-RABV llama-derived VHH nanobodies complexed with a transfection agent. One of the VHHs was able to reduce the viral load in mice, but no significant effect on survival was detected. Though not completely effective, nanobody therapy could be attempted in association with other antivirals to improve therapies against rabies.Keywords
Funding Information
- São Paulo Research Foundation (2022/07115-7)
- São Paulo Research Foundation (302503 2021-8)
- Brazilian National Council for Scientific and Technological Development (2022/07115-7)
- Brazilian National Council for Scientific and Technological Development (302503 2021-8)
This publication has 14 references indexed in Scilit:
- A combination of two human monoclonal antibodies cures symptomatic rabiesEMBO Molecular Medicine, 2020
- Intracerebral transfection of anti-rabies virus antibodies is an effective therapy for rabiesJournal of NeuroVirology, 2020
- Short interfering RNAs targeting a vampire-bat related rabies virus phosphoprotein mRNABrazilian Journal of Microbiology, 2017
- Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat CancerEBioMedicine, 2016
- Critical Appraisal of the Milwaukee Protocol for Rabies: This Failed Approach Should Be AbandonedCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2015
- Protective Effect of Different Anti-Rabies Virus VHH Constructs against Rabies Disease in MicePLOS ONE, 2014
- Human rabies: neuropathogenesis, diagnosis, and managementThe Lancet Neurology, 2013
- Cell‐penetrating anti‐GFAP VHH and corresponding fluorescent fusion protein VHH‐GFP spontaneously cross the blood‐brain barrier and specifically recognize astrocytes: application to brain imagingThe FASEB Journal, 2012
- A universal real-time assay for the detection of LyssavirusesJournal of Virological Methods, 2011
- Single domain antibodies: promising experimental and therapeutic tools in infection and immunityMedical Microbiology and Immunology, 2009